Marianne Stanford, PhD, shares her career path that led to joining IMV Inc, a Halifax-based biotech company, almost 10 years ago. She also describes IMV's efforts to leverage their cancer immunotherapy technology and expertise towards developing an effective COVID19 vaccine.
Dr. Stanford is current Vice-President, Research and Development at IMV Inc, a Halifax based biotechnology company overseeing all preclinical research activities and clinical immunology assessment of cancer immunotherapies and infectious disease vaccines. She received her BSc and MSc from Memorial University of Newfoundland and her PhD from Dalhousie University. She performed post-doctoral research with Dr. Grant McFadden at Western University (London, Ontario) and Dr. John Bell at Ottawa Hospital Research Institute.
The S2BN Podcast, hosted by the S2BN's Founder and CEO, Bruce Seet, features conversations with scientists, leaders and individuals who are working at the interface of science, innovation and business. We hear their career journeys, stories, insights and advice that have enabled them to change the world through science and business.
The Science to Business Network (S2BN) is a multi-chapter, non-profit organization that aims to promote innovative thinking, professional development, entrepreneurialism and networking among scientists, industry professionals and other stakeholders within the innovation ecosystem. For more information, visit our website at www.s2bn.org.